Tagged with GE

Canada Jaiveer Singh, CEO of Mint Pharmaceuticals explains the company’s business model and how it fits the characteristics of the Canadian market on the tenth anniversary of the company. He further highlights how Mint’s portfolio of boutique generics is sure to grow over the coming years to meet the specific needs…

Canada Tarik Henein, president of Generic Medical Partners, explains the company’s commitment to improving the lives of Canadians by connecting global generic development and manufacturing companies with the Canadian market. He further comments on the key points for navigating the complex Canadian pharmaceutical market and how GMP combines a unique flexibility…

Poland Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to find a sustainable balance between government and industry to ensure patients receive world-class healthcare. Furthermore, they highlight the importance of…

Serbia Nenad Djordjevic, managing director of Esensa, introduces the Belgrade company’s 200-strong portfolio of medical devices, food supplements, cosmetics and general use items; how it is now exporting its ‘made in Serbia’ products to geographies as diverse as Kazakhstan and Hong Kong; and how Esensa is breaking down stereotypes of what…

Poland Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore, he highlights the strategic importance of Poland in the region as the company’s footprint continues to grow and highlights the…

Lithuania Janis Kalejs, country manager Baltics at Mylan, discloses the strategies he has used to successfully lead his affiliate through corporate changes and explains how Mylan aims to continue providing affordable as well as high-quality treatments to patients in the region. What is the history of Mylan in the Baltics? “The…

Serbia Ana Popovic, general manager of Serbia’s generics association, Genezis, gives her thoughts on how the generics industry has progressed in the country, what room for improvement remains, and the impact of EU succession. Where does Genezis stand in 2017 and what is keeping you busy at the moment? “The Serbian…

Canada The government of the French-speaking Canadian province of Québec stands out for undertaking healthcare reforms while appreciating the need to join hands with industry when it comes to the promotion of health innovation. “Quebec has the most aggressive approach of any province in this country [for generics pricing]” Dr. Gaétan…

Poland Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way. Moreover, she highlights the importance of achieving reimbursement for three key products for Multiple Sclerosis and Oncology as well as…

Serbia Milos Davidovic, Mylan’s country manager responsible for Serbia, Slovenia, Macedonia, and Montenegro, reveals the made-to-measure market approach that he has been implementing in the region for the past six years while highlighting the crucial role of employing a highly educated, expert workforce. What potential did Mylan see in Serbia, and…

Poland Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better market access to their biofactor therapies. Furthermore, he discusses the need to highlight the pharmacoeconomic impact of their products to…

Brazil Poul Sorensen, director of Geistlich Pharma in Brazil, details the importance of educational activities for Geistlich’s business, the affiliate’s desire to bring new segments of Geistlich’s portfolio to Brazil and the necessity of adapting the business strategy to each region in Brazil according to their price sensitivity. Could you introduce…